Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps

Medtronic has received FDA approval to pair its latest glucose sensor, Simplera Sync, with its MiniMed 780G insulin pump, enabling an integrated automated insulin delivery system. The company plans a limited launch of the sensor this fall and expects the update—along with its collaboration with Abbott on a new glucose monitor—to significantly boost its U.S. diabetes business. The Simplera Sync sensor is smaller than previous models, requires no finger sticks or tape, and supports more seamless insulin management.

This FDA clearance is a major milestone as Medtronic works to revitalize its diabetes division following the resolution of a 2023 FDA warning letter. The MiniMed 780G system offers advanced features like automatic meal detection and lower glucose targets, helping patients who may forget or miscalculate insulin doses. Medtronic is also pursuing approval to expand the use of its 780G system to people with Type 2 diabetes and is continuing to invest in proprietary CGM technology exclusive to its devices.